Alicia McElhaney

Recent Articles By The Author

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Mylan Falls on FDA Warning on Quality Control

Mylan Falls on FDA Warning on Quality Control

The EpiPen-maker has received a letter from the FDA about its manufacturing facility in Nashik, India.

Biotech Movers Trading Positive Ahead of Market's Open

Biotech Movers Trading Positive Ahead of Market's Open

Intellia Therapeutics led the movers.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Endo international, AngioDynamics Lead Biotech Movers

Endo international, AngioDynamics Lead Biotech Movers

Endo International slipped 5% ahead of market's open Friday.

Dollar Store Debacle Bodes Poorly for Walgreens-Rite Aid Merger

Dollar Store Debacle Bodes Poorly for Walgreens-Rite Aid Merger

Sycamore Partners' attempt to purchase divested dollar stores went poorly. Will the FTC believe Fred's can do better with Rite Aid spinoffs?

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Walgreens Has 'Strong Argument' to Push Rite Aid Deal Passed Regulators, CEO Pessina Says

Walgreens Has 'Strong Argument' to Push Rite Aid Deal Passed Regulators, CEO Pessina Says

The two companies initially agreed to an acquisition agreement in October 2015.

Valeant Shares Close Below $10 for First Time Since 2008

Valeant Shares Close Below $10 for First Time Since 2008

Can the drugmaker bounce back?

Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

Investors are ticked off about the CEO's bonanza amid dismal results.